Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

461.43 -9.89 (-2.10%)
Streaming Delayed Price Updated: 12:22 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 129,972
Open 474.90
Bid (Size) 461.00 (5)
Ask (Size) 461.77 (4)
Prev. Close 471.32
Today's Range 460.00 - 476.20
52wk Range 327.73 - 539.78
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
From argenx SE
Via GlobeNewswire
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
From argenx SE
Via GlobeNewswire

Performance

YTD
+21.11%
+21.11%
1 Month
+16.97%
+16.97%
3 Month
+25.13%
+25.13%
6 Month
+26.58%
+26.58%
1 Year
-11.52%
-11.52%

More News

Read More
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
From Zai Lab Limited
Via Business Wire
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
From argenx SE
Via GlobeNewswire
Breaking Down argenx: 12 Analysts Share Their Views
Via Benzinga
The Analyst Verdict: argenx In The Eyes Of 12 Experts
Via Benzinga
Why Is European Drugmaker Argenx Stock Trading Higher On Monday?
Via Benzinga
Exposures Product Safety
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
Via Investor's Business Daily
Exposures Product Safety
Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
From argenx SE
Via GlobeNewswire
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
From argenx SE
Via GlobeNewswire
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
Via Investor's Business Daily
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
Via Benzinga
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
Via Investor's Business Daily
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ARGX Stock Earnings: argenx Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx announces results of Annual General Meeting of Shareholders
From argenx SE
Via GlobeNewswire
argenx to Present at BofA Securities 2024 Health Care Conference
From argenx SE
Via GlobeNewswire
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
From argenx SE
Via GlobeNewswire
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
From argenx SE
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.